New steps on an old path: Novel estrogen receptor inhibitors in breast cancer
Martina Pagliuca(Institut Gustave Roussy), Mario Giuliano(Regione Campania), Meghna Trivedi(University of Houston), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmine De Angelis(Baylor College of Medicine), Grazia Arpino(University of Naples Federico II), Mario Rosanova(Fondazione Europea Ricerca Biomedica), Agostina Lagodin D’Amato(Ospedale Policlinico San Martino), Roberta Scafetta(Campus Bio Medico University Hospital), Lucia Del Mastro(Ospedale Policlinico San Martino), Marco Donato(Università Campus Bio-Medico), Fabrice André(Inserm), Anna Orsola Maria Russo, Fabio Puglisi(University of Udine)
Cited by 23
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k